Vera Says About Half Of Its $10 Million Launch-Quarter Trutakna Sales Went To Inventory

Vera's commercial chief expects the demand share of sales to climb "much higher" in coming quarters, with a 50% covered-lives goal set for year-end.

Share
Vera Says About Half Of Its $10 Million Launch-Quarter Trutakna Sales Went To Inventory

Only about half of Vera Therapeutics' first partial quarter of Trutakna sales reflected patient demand, Chief Commercial Officer Matt Skelton told analysts on the company's earnings call Thursday. The rest went into inventory, he said, answering a Wells Fargo analyst's question about the roughly $10 million in sales.

Half demand, half stocking

Asked how much of the sales was stocking versus demand, Skelton said: "about half of that is demand, about half is inventory." He added, "we fully expect that ratio to go much higher for demand in the next quarters."

Chief Financial Officer Sean Grant put net product revenue at $10.3 million for the third quarter, the first partial quarter of commercial sales after the July 7 accelerated approval. Cost of sales was $3.3 million. The quarterly net loss was $93.7 million, or $1.30 per share, against $80.3 million, or $1.26 per share, a year earlier.

Start forms carry the demand case

Vera, a late clinical-stage biotech whose drug atacicept is sold as Trutakna for the autoimmune kidney disease IgA nephropathy, pointed to patient start forms as its demand gauge. CEO Marshall Fordyce said the company has received about 700 since approval, and Skelton said they are not driven by a small cohort of physicians.

Skelton said the forms come almost entirely from patients already diagnosed and on backbone therapy such as steroids and SGLT2 drugs, with many previously on Filspari and Tarpeyo. He called the move to Trutakna "almost a graduation" rather than switching.

Fordyce said future updates will report start forms through the end of the prior quarter, not the call date.

Coverage goal and cash

Skelton said Vera is on track for 50% of covered lives by year-end. He said branded step-throughs required by some payers, usually involving Filspari or Ventrafia, affect the B-cell class in the same way.

Vera ended September with $384 million in cash, equivalents and marketable securities. It drew $75 million from its debt facility in late October, which Grant said would have lifted the balance to $459 million on a pro forma basis, and up to $350 million remains available subject to conditions.

This week the company filed a supplemental application seeking full FDA approval, with a decision anticipated in mid-2027.

Vera is scheduled to appear at the Guggenheim healthcare conference in a fireside chat on Tuesday, November 10.

Sources